Evidence map›Paper›PMID 29748469›Full record

ReviewNanomaterials (Basel, Switzerland)2018

Silver Nanoparticles: Synthetic Routes, In Vitro Toxicity and Theranostic Applications for Cancer Disease.

Valeria De Matteis, Mariafrancesca Cascione, Chiara Cristina Toma, Stefano Leporatti

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed.

  1. Enhanced anticancer efficacy ofMaterials today. Bio · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Current pharmaceutical biotechnology · 2026
    Article
  7. Article
  8. Nanocarriers for cutting-edge cancer immunotherapies.Journal of translational medicine · 2025
    Review
  9. Article
  10. Nanotheranostics: A Cutting-edge Technology for Cancer Management.Current pharmaceutical biotechnology · 2025
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. PluronicGels (Basel, Switzerland) · 2023
    Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Valeria De MatteisDipartimento di Matematica e Fisica "E. De Giorgi", Università del Salento, Via Monteroni, 73100 Lecce, Italy. valeria.dematteis@unisalento.it.
Mariafrancesca CascioneDipartimento di Scienze Biomediche e Oncologia Umana, Università degli Studi di Bari "Aldo Moro", p.zza G. Cesare, 70124 c/o Policlinico Bari, Italy. mariafrancesca.cascione@unisalento.it.
Chiara Cristina TomaDipartimento di Matematica e Fisica "E. De Giorgi", Università del Salento, Via Monteroni, 73100 Lecce, Italy. chiara.toma@unisalento.it.
Stefano LeporattiCNR Nanotec-Istituto di Nanotecnologia, c/o Campus Ecotekne, Via Monteroni, 73100 Lecce, Italy. stefano.leporatti@nanotec.cnr.it.ORCID 0000-0001-5912-7565

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The large use of nanomaterials in many fields of application and commercial products highlights their potential toxicity on living organisms and the environment, despite their physico-chemical properties. Among these, silver nanoparticles (Ag NPs) are involved in biomedical applications such as antibacterial agents, drug delivery vectors and theranostics agents. In this review, we explain the common synthesis routes of Ag NPs using physical, chemical, and biological methods, following their toxicity mechanism in cells. In particular, we analyzed the physiological cellular pathway perturbations in terms of oxidative stress induction, mitochondrial membrane potential alteration, cell death, apoptosis, DNA damage and cytokines secretion after Ag NPs exposure. In addition, their potential anti-cancer activity and theranostic applications are discussed.

Indexed as

silver nanoparticlessynthetic routestheranosticstoxicity

Identifiers

PMID29748469
PMCPMC5977333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.